Clinical trials: Drug Administration, Inhalation
Asthma
A Study to Evaluate the Amount of Drug That Becomes Available to the Blood Circulation When Inhaled by a Nebulizer and Dry Powder Inhaler in Healthy Subjects.
The purpose of this study is to assess the relative bioavailability of the AZD7594 nebulized formulations (test) and the dry powder formulation (reference).
- Trial name
- NCT04072562
- Testing
- AZD7594
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents
A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults…
- Trial name
- NCT01159912
- Testing
- Fluticasone propionate, Fluticasone furoate
- Where
- 82 sites in United States, Belgium and 3 more
- Volunteers
- 350 people
- Sponsor
- GlaxoSmithKline
Asthma
A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
The purpose of this study is to describe the use of rescue medication and quality of life in adult asthmatic patients, either treated with SYMBICORT SMART® (regular dose according to physician's prescription and the current…
- Trial name
- NCT00884689
- Where
- 43 sites in Germany
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients
This study is designed to determine the efficacy and safety of a new long-acting beta-agonist for asthma patients (GSK159797) following dosing for 14 days.
- Trial name
- NCT00358488
- Testing
- GSK159797 (10, 15, and 20mcg), salbutamol, salmeterol 50mcg
- Where
- 6 sites in Germany, Netherlands and 3 more
- Volunteers
- 54 people
- Sponsor
- GlaxoSmithKline
Bioequivalence, Asthma
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT04746040
- Testing
- Test, Reference
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma
A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole
A randomized two-way crossover study to determine whether concomitant administration of CYP P450 3A4 inhibitor ketoconazole and fluticasone furoate/GW642444M combination significantly increases the systemic effects and exposure…
- Trial name
- NCT01165125
- Testing
- FF / GW642444, ketoconazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bioequivalence
Bioequivalence Study for Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT05982990
- Testing
- Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 250/50
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
To Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (albuterol sulfate) Inhalation Aerosol, eq 90 mcg base (Teva Respiratory…
- Trial name
- NCT03528577
- Testing
- Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Idiopathic Parkinson's Disease
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
This randomized, multicenter, placebo-controlled, double-blind study will evaluate the efficacy and safety of inhaled CVT 301 compared with placebo in PD patients experiencing motor response fluctuations (OFF phenomena) as an…
- Trial name
- NCT01777555
- Testing
- CVT-301
- Where
- 22 sites in United States, Italy and 2 more
- Volunteers
- 89 people
- Sponsor
- Acorda Therapeutics
Healthy
Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)
This study aims to demonstrate the bioequivalence between the formulation of Budesonide 1mg/2mL nebuliser suspension (IMP 08P1707F0) relaive to the reference product Pulmicort(r) 1.0mg/2mL suspension.
- Trial name
- BUNIPILOT (NCT06595121)
- Testing
- budesonide, Activated Charcoal
- Where
- Turkey (Türkiye)
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Unither Pharmaceuticals, France
Pulmonary Disease, Chronic Obstructive
ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the clinic 10 times.
- Trial name
- NCT00144911
- Testing
- Salmeterol, Fluticasone Propionate/Salmeterol Combination Product
- Where
- 97 sites in United States, Canada
- Volunteers
- 740 people
- Sponsor
- GlaxoSmithKline
Asthma
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not…
- Trial name
- NCT01436071
- Testing
- Fluticasone furoate 50mcg
- Where
- 24 sites in United States, Mexico and 2 more
- Volunteers
- 248 people
- Sponsor
- GlaxoSmithKline
Bioequivalence
Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT06025214
- Testing
- Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS® 500/50
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bioequivalence
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- BREATH-PK500 (NCT03751202)
- Testing
- Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg, ADVAIR DISKUS
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma
Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication
Determine the 24-hour FEV1-profile of tiotropium solution for inhalation after 4 weeks treatment periods of 5 mcg tiotropium administered once daily in the evening and 2.5 mcg tiotropium administered twice daily (morning and…
- Trial name
- NCT01696071
- Testing
- Tiotropium 5 mcg qd, Tiotropium 2.5 mcg bid
- Where
- 22 sites in Austria, Germany and 2 more
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Bioequivalence, Asthma
Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT05085587
- Testing
- Test, Reference
- Where
- Greece
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Asthma, Bronchial, Bronchial Asthma
Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
- Trial name
- NCT00189722
- Testing
- Tacrolimus
- Where
- 28 sites in Czechia, Germany and 3 more
- Volunteers
- 160 people
- Sponsor
- Astellas Pharma Inc
Asthma
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder and fluticasone furoate inhalation powder both administered once daily in adolescent and adult subjects…
- Trial name
- NCT01165138
- Testing
- Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 70 sites in United States, Germany and 4 more
- Volunteers
- 612 people
- Sponsor
- GlaxoSmithKline
Bioequivalence
Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT05697003
- Testing
- Fluticasone propionate 1000 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals, ADVAIR DISKUS 100/50
- Where
- Greece
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Bioequivalence
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT03894280
- Testing
- Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals, SERETIDE DISKUS® 250/50 inhalation powder/GSK, Activated Charcoal suspension
- Where
- Greece
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.